JP2542792C - - Google Patents

Info

Publication number

JP2542792C

JP2542792C JP2542792C JP 2542792 C JP2542792 C JP 2542792C JP 2542792 C JP2542792 C JP 2542792C

Authority

JP

Japan

Prior art keywords

reservoir

user

patient

medicament

reservoirs

Prior art date

1999-05-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 74
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 22
• 239000002550 vasoactive agent Substances 0.000 claims description 21
• 150000001875 compounds Chemical class 0.000 claims description 18
• 230000004888 barrier function Effects 0.000 claims description 16
• 239000003589 local anesthetic agent Substances 0.000 claims description 12
• 239000012876 carrier material Substances 0.000 claims description 8
• 239000007864 aqueous solution Substances 0.000 claims description 6
• 239000003792 electrolyte Substances 0.000 claims description 6
• 210000004400 mucous membrane Anatomy 0.000 claims description 6
• 239000005526 vasoconstrictor agent Substances 0.000 claims description 5
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
• 230000004913 activation Effects 0.000 claims description 4
• 150000002500 ions Chemical class 0.000 claims description 4
• 229960004194 lidocaine Drugs 0.000 claims description 4
• 230000015556 catabolic process Effects 0.000 claims description 3
• 238000006731 degradation reaction Methods 0.000 claims description 3
• 239000012895 dilution Substances 0.000 claims description 3
• 238000010790 dilution Methods 0.000 claims description 3
• 238000010521 absorption reaction Methods 0.000 claims description 2
• 229940079593 drug Drugs 0.000 description 27
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• 239000000243 solution Substances 0.000 description 13
• 238000000034 method Methods 0.000 description 10
• YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 239000004033 plastic Substances 0.000 description 5
• 229920003023 plastic Polymers 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 229920000742 Cotton Polymers 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• NDNSIBYYUOEUSV-RSAXXLAASA-N (S)-ropivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C NDNSIBYYUOEUSV-RSAXXLAASA-N 0.000 description 3
• 239000012790 adhesive layer Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• -1 for example Substances 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• 230000002227 vasoactive effect Effects 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 239000013583 drug formulation Substances 0.000 description 2
• 230000005684 electric field Effects 0.000 description 2
• 230000000887 hydrating effect Effects 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 229960003691 ropivacaine hydrochloride monohydrate Drugs 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229920002994 synthetic fiber Polymers 0.000 description 2
• 239000012209 synthetic fiber Substances 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 108010045937 Felypressin Proteins 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000005452 bending Methods 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000005370 electroosmosis Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• SFKQVVDKFKYTNA-DZCXQCEKSA-N felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 description 1
• 229960001527 felypressin Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000009434 installation Methods 0.000 description 1
• 238000002690 local anesthesia Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 229940053973 novocaine Drugs 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000013271 transdermal drug delivery Methods 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1